Cardiovascular Risk and Chronic Obstructive Pulmonary Disease

Summary

The principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (CVR) in COPD patients, using multivariate analysis.

Eligibility

Inclusion Criteria:

For patients with stable COPD:

* Men or women aged 18 to 85
* FEV1/FVC \< 70% or proven BPCO
* Patients who have given their free and informed consent in writing

For patients with decompensated COPD:

* Men or women aged 18 to 85
* FEV1/FVC \< 70% or proven BPCO
* At the time of acute respiratory failure (ARF), when admitted to hospital:

  * Respiratory rate \> 25 cycles per minute
  * PaCO2 \> 45 mmHg
  * blood pH \< 7.35
* When included in the study:

  * pH \> 7.33 at the end of ARF, 2 days in a row, or 3 to 7 days post-D1 decompensation (admission to the hospital)
  * Fever \< 38.5°C
* Patients who have given their free and informed consent in writing

Exclusion Criteria:

* Obvious evolving infection or CRP \> 100 mg/L
* Cardiac decompensation considered the main cause of decompensation or chronic heart failure with LVEF \< 45%
* Evolving neoplasia
* On antioxidants: N-acetyl-cysteine, selenium, vit. C, vit. E
* Pregnant or nursing women
* Patients under tutorship or curatorship
* Patients participating in a drug clinical research study
* Patients not affiliated to the French social security system (or equivalent)
* Patients deprived of liberty or hospitalized without consent.

Conditions2

Browse More Trials